Prevest Denpro Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Growth improved but remains below aspiration: Revenue grew 13.6% to INR 67.09 crores, an improvement over recent ~10% years but well short of the 30% the company once targeted, with management citing market deflation and external uncertainties.
• Margins held firm despite cost pressure: EBITDA margin stayed at 38.98% as operational efficiencies and cost optimization offset raw material and logistics inflation, with the second half improving to 39.15%.
• Digital dentistry is the big strategic bet: The company is building 3D printers, resins, and scanners to offer an end-to-end digital workflow, a move management frames as existential: diversify now or risk being left behind.
• The U.S. pivot is working: Revenue from the U.S. reached 14% of the total, helped by the Axiodent subsidiary that solved the "made in India" label resistance among American dentists.
• What to watch next quarter: Whether the 3D printer launches commercially and gains traction, the pace of contribution from Oradox and 3D resins, and any firming of the revenue growth outlook beyond the aspirational 13% baseline.

Revenue Performance & Drivers

• Q4 surge, but not a new baseline: Q4 revenue jumped 21.79% QoQ to INR 19.53 crores, which management called "extremely good" but declined to commit to sustaining that run rate, noting Q4 is always seasonally the strongest quarter.
• Domestic engine steady: Domestic sales grew 13%, driven by deeper rural penetration through new dealer appointments and the Prevest Direct initiative, alongside metro and chain-clinic tie-ups.
• Exports recovering: Export business contributed 10% growth, with countries previously hit by forex crises and regional instability now showing signs of stabilization.
• Top products concentrating: The top 20 products now contribute 60% of total revenue, up from 55% previously, indicating a narrowing of the revenue base toward the strongest SKUs.
• Dealer model limits end-user visibility: Repeat rates at the dealer level are high, but the company cannot track repeat rates at the individual dentist level because it supplies through intermediaries, not directly.

Namrata Modi: "Yes, our growth rates this year have not been spectacular, but I would rather deliver consistent profitable growth than chase unsustainable numbers that compromise our long-term position."

Digital Dentistry & Diversification

• 3D printer development complete, launch imminent: The company has developed its own LCD-based 3D printer with in-house design and component sourcing; market testing is done, sample pieces are in the market, and response is described as very good.
• 3D resins already contributing modestly: 3D resins brought in approximately INR 45 to 50 lakhs this fiscal year, a small base from which the company expects growth as the digital workflow proposition expands.
• Intraoral scanner on the roadmap: The company plans to enter intraoral scanning technology in the near future, aiming to complete a full digital portfolio from diagnosis through design, fabrication, and finishing.
• Bio-based resin R&D underway: Materials teams are developing sustainable bio-based 3D resins for dental applications, positioning for a future where sustainability matters in procurement.
• Diversification framed as existential: Management stated bluntly that without diversifying into digital dentistry, "we will be out very soon," because market trends are moving toward digital workflows and competitors are already there.
• Consolidation will take years: The company estimates it may take 4 years to consolidate its position in the market from a start today, and that after 5 to 10 years it will be in a better position to face competition.

Sai Kalyan: "This is because by 2030, we believe that digital workflows will no longer be optional for dentists, and they will be an active part of each and everyone's life."

U.S. Market & Axiodent

• The label problem was real: Dentists in the U.S. resisted "made in India" labels, so the company incorporated Axiodent Inc.; products are now manufactured in India but labeled for the U.S. entity, improving brand acceptability.
• Early traction visible: The subsidiary has already secured substantial orders and established private labeling partnerships, opening new revenue streams beyond the company's own brands.
• U.S. revenue share rising: The U.S. contributed 14% of revenue this year, up from a smaller base, and management sees it as a high-priced market representing 40% of the global dental market.

Atul Modi: "Actually, we started with the marketing of previous products in the U.S., which are made in India label, but we found that the dentists are not happy with the made in India label. So we decided to incorporate a company in the U.S."

New Products & R&D Pipeline

• Three products ready for launch: Crysta Axis (strontium-enriched restorative), Caries Cure SDF (silver diamine fluoride system), and Crysta LC RMGI (resin-modified glass ionomer) have been developed and are ready for national and international markets, all 100% indigenously developed.
• 4 to 5 more launches expected in FY26: The company plans to launch at least 4 to 5 new products in the 2025-2026 fiscal year, focused on performance, safety, and clinical excellence.
• Raw material commercialization beginning: The company has scaled up production of core biomaterials (hydroxyapatite, tricalcium phosphate, bioglass, mineral trioxide aggregate) and is now preparing to sell these globally to other manufacturers and medical device suppliers.
• R&D center recognized by government: The company operates a state-of-the-art R&D center recognized by the Ministry of Science and Technology, described as one of the best and the only central research center of its kind in India.

Oradox & Oral Care

• Oradox contributed ~INR 50 lakhs this year: The new oral care brand is in its first year and getting good response, with a marketing strategy and plan in place.
• FY26 expected to be better: Management hopes that next year will be a better year for Oradox, noting that having reached this level in one year, the brand should reach a better level in 2026.
• Brand-building against incumbents: The company acknowledged it is a 25-year-old brand competing with multinationals that are 100 years old with better brand value, so building Oradox will take time.

Atul Modi: "See, the brand is a new brand. Our company is not old. It's 25 years old, while we are competing with multinational companies which are 100 years old. So they have better brand value, compared to that we are a smaller company."

Margins, Costs & Balance Sheet

• EBITDA margin held at 38.98%: Despite significant inflationary pressure on raw materials and logistics, margins stayed flat year-on-year, with the second half improving to 39.15% from 38.21% in the prior corresponding period.
• Operational levers deployed: Lean manufacturing, ERP upgrades, and supply chain optimization drove better asset utilization, reduced working capital requirements, and improved production flexibility.
• Marketing spend stable going forward: Exhibition and marketing expenses (2.64% of revenue) and tour/traveling (1.23%) are not expected to increase much, as the company already covers almost all important exhibitions globally and the marketing team is in execution mode.
• Management salaries not up for optimization: When an analyst suggested reducing director salaries (INR 1.2 crores each) to improve margins, management declined, noting no salary increase in 5 years and that the amounts are commensurate with market and would not materially move profitability.
• Balance sheet supports counter-cyclical moves: The company has a robust balance sheet with healthy cash flows and an optimal debt ratio, providing flexibility for strategic investments when opportunities arise.

Atul Modi: "We are not just maintaining liquidity, we are positioning ourselves to capitalize on market opportunities when they emerge."

Guidance & Commitments

Key Metrics